bioAffinity Technologies

bioAffinity Technologies is a biotechnology company focused on developing non-invasive, early-stage cancer diagnostics and targeted cancer treatments. Their flagship product, CyPath® Lung, is a laboratory-developed test (LDT) that utilizes advanced flow cytometry to analyze sputum samples and identify early-stage lung cancer, the leading cause of cancer-related deaths. CyPath® Lung aims to improve diagnostic accuracy, leading to increased survival rates, fewer unnecessary invasive procedures, and reduced patient anxiety and medical costs.

bioAffinity Technologies has a strong research and development team dedicated to expanding their core porphyrin platform technology. They actively engage with the scientific community through peer-reviewed publications and conference presentations. The company's commitment to innovation and improving patient outcomes positions them as a leading player in the fight against cancer.

bioAffinity Technologies is dedicated to addressing the urgent need for non-invasive, early-stage cancer diagnosis and targeted cancer treatment. Their primary focus is on developing tests and therapies that detect and treat cancer at the cellular level. Their flagship product, CyPath® Lung, is a non-invasive test that assists physicians in making clinical decisions for patients with suspicious lung nodules identified during low-dose CT screening. CyPath® Lung accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to significantly increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.

bioAffinity Technologies promotes a culture of innovation, collaboration, and a shared commitment to improving the lives of cancer patients. The company is driven by a deep passion for scientific discovery and a dedication to bringing life-saving diagnostics and therapies to market. This dedication is fostered through a collaborative and supportive environment where scientists, executives, and other professionals work together to achieve common goals. bioAffinity values diversity, inclusivity, and the contributions of all team members.

bioAffinity Technologies demonstrates a commitment to diversity, equity, and inclusion through its leadership and board composition, actively promoting a diverse team of scientists and executives. While the company website does not explicitly state a DEI policy or specific initiatives, it highlights the diverse backgrounds and accomplishments of its leadership and board members. This suggests a focus on fostering a workplace that values diverse perspectives and experiences to drive innovation and success in the fight against cancer.